VieCuri Medisch Centrum
Welcome,         Profile    Billing    Logout  
 35 Trials 
78 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wouw, Y van der
LyRICX, NCT03764553: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Recruiting
2
320
Europe
Liposomal Irinotecan, Carboplatin, Capecitabine, Xeloda, Oxaliplatin, 5-fluorouracil, Leucovorin
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Servier
Esophageal Cancer
07/25
07/26
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Wouw, A J van der
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
Bouman, Esther
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
Jeong, Joon
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
4
2076
Europe, Canada, US, RoW
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance
Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Motor Function, Cognitive Function, Contrast Media
12/28
12/28
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
Sonke, Gabe S
TRAIN-2, NCT01996267: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer,

Active, not recruiting
3
437
Europe
PTC+Pertuzumab, Paclitaxel; 80 mg/m2; day 1,8, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1, Carboplatin; AUC=6; day 1, Pertuzumab; 420 mg (loading dose 840 mg); day 1, FEC-T+Pertuzumab, Fluorouracil; 500 mg/m2; day 1, Epirubicine; 90 mg/m2; day 1, Cyclophosphamide 500 mg/m2; day 1, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg)
The Netherlands Cancer Institute, Roche Pharma AG, Borstkanker Onderzoek Groep
Breast Cancer, HER2 Positive
12/18
12/30
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
TRAIN-4, NCT06162559: Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the Study

Recruiting
1
30
Europe
Tucatinib, Tukysa, Trastuzumab, Herceptin, Pertuzumab, Perjeta
The Netherlands Cancer Institute, Seagen Inc.
Breast Cancer
08/26
05/36
Bool, Coby van de
NCT05335525: Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

Recruiting
N/A
230
Europe
Closure of the femoral arterial puncture site
Terumo Europe N.V., Terumo Medical Corporation
Vascular Closure, Endovascular Procedure, Hemostasis, Peripheral Vascular Disease, Femoral Artery
05/23
05/23
Cremolini, Chiara
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Completed
1/2
29
Europe, US
MEN1611, Cetuximab
Menarini Group, Menarini Ricerche S.p.A.
Metastatic Colorectal Cancer
01/24
02/24
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
275
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
Wouw, Agnes J van de
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Nishina, Tomohiro
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Antonuzzo, Lorenzo
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT02687958: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Active, not recruiting
2
30
Europe
Everolimus, Afinitor
Gruppo Oncologico Italiano di Ricerca Clinica, Novartis
Neuroendocrine Carcinoma
12/22
12/23
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients With NET

Active, not recruiting
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
09/24
09/24
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Recruiting
N/A
600
Europe
MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa
Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
06/25
06/25
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
Pillinger, Michael
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
Wouw, AJ Van De
DIRECT-2, NCT05503108: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Suspended
3
10
Europe
Fasting Mimicking diet program, Xentigen™
Leiden University Medical Center, The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Comprehensive Cancer Centre The Netherlands, Koningin Wilhelmina Fonds, World Cancer Research Fund International, L-Nutra Inc
Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Pathological Complete Response, Objective Response Rate, Neoadjuvant Chemotherapy
01/24
01/24
Boon, Eline
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Yamaguchi, Kensei
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Active, not recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
07/24
10/25
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
Lorenzo, Jose Juan Ponce
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
DEMETHER, NCT06172127: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Recruiting
2
165
Europe, US
Trastuzumab deruxtecan, T-DXd, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, PHESGO, Pertuzumab-Trastuzumab FDC SC, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
MedSIR, Hoffmann-La Roche
HER2-positive Breast Cancer
11/26
05/29
ARCTIC-2, NCT05542082: Pilot Study of the CHILLS Cryotherapy System for the Treatment of OSA

Active, not recruiting
N/A
50
RoW
CHILLS Procedure
Cryosa, Inc.
Obstructive Sleep Apnea of Adult
12/23
04/27
Hickey, Eve
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
Wouw, Yes J van de
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Khanna, Puja
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
Sunakawa, Yu
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Active, not recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
07/24
10/25
Takashima, Atsuo
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
Remkes, W
CELEBRATE, NCT04825743 / 2020-003320-16: A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

Recruiting
3
2499
Europe, Canada, RoW
zalunfiban, RUC-4, Placebo
CeleCor Therapeutics, CeleCor Therapeutics, Inc.
ST-elevation Myocardial Infarction (STEMI)
12/24
12/24
Esaki, Taito
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Davidis, MA
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Santabarbara, Giuseppe
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Arnoldussen, Carsten
NCT05335525: Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

Recruiting
N/A
230
Europe
Closure of the femoral arterial puncture site
Terumo Europe N.V., Terumo Medical Corporation
Vascular Closure, Endovascular Procedure, Hemostasis, Peripheral Vascular Disease, Femoral Artery
05/23
05/23
Hamming, Lisanne
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
Sousa, Rita Teixeira
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Troquay
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Tadamichi, Denda
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Elshof, Jan-Willem
NCT06218875: Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

Recruiting
N/A
3500
Europe, US
W.L.Gore & Associates
AAA - Abdominal Aortic Aneurysm
09/42
09/42
Agterof, Mariette
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
Asayama, Masako
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Madeira, Pedro
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
Tischner
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Nishizawa, Yujiro
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
Inagaki, Chiaki
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26

Download Options